Neola Medical

Neola Medical Gross Margin

The Gross Margin of Neola Medical (NEOLA.ST) as of Oct 27, 2026 is -1,176.96 %. In the previous year, Gross Margin was -25,329.03 % — a change of -95.35% (higher).

Gross Margin

-1,176.96 %

YoY

-95.35%

Last updated:

Gross Margin of Neola Medical is 2021 -1,176.96 % . Gross Margin of Neola Medical was 2020 -25,329.03 % . It decreases by -95.35% higher compared to the previous year.

Neola Medical's gross margin stands at -1,177.0%, down from 147.8% several years earlier.

The Neola Medical Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2016
83.29 SEK
Jan 1, 2017
147.82 SEK
Jan 1, 2018
-220.35 SEK
Jan 1, 2019
-19,762.50 SEK
Jan 1, 2020
-25,329.03 SEK
Jan 1, 2021
-1,176.96 SEK
The Neola Medical Gross Margin history
YEARGross MarginYoY
-1,176.96 %-95.35%
-25,329.03 %+28.17%
-19,762.50 %+8,868.77%
-220.35 %-249.06%
147.82 %+77.48%
83.29 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neola Medical Stock analysis

What does Neola Medical do? Neola Medical AB commercializes medical devices based on its patented GASMAS technology for continuous lung monitoring in premature babies. The company's primary product, NEOLA, provides real-time alerts for life-threatening complications by measuring lung volume changes and oxygen concentration. Neola Medical targets neonatal intensive care units as its key market segment, serving healthcare providers who require advanced monitoring solutions for premature infants. The firm's revenue model relies on selling the NEOLA device and associated technology to hospitals and medical facilities specializing in neonatal care. The company's business concept centers on the commercialization of its medical technology product for continuous lung monitoring, leveraging the GASMAS (Gas in Scattering Media Absorption Spectroscopy) technology. Neola Medical focuses on the neonatal intensive care market segment, where its device offers continuous monitoring capabilities that address critical needs in premature infant care. The primary purpose of the NEOLA device is to support neonatal intensive care through real-time monitoring and alerts for complications. Neola Medical AB's revenue streams come from the sale of the NEOLA medical device and its underlying technology to healthcare institutions. The company targets neonatal intensive care units as its primary customer segment, focusing on hospitals and medical facilities that provide specialized care for premature babies. The firm's business model is built around the commercialization of its patented GASMAS technology through the NEOLA device, which addresses specific monitoring needs in neonatal care. Neola Medical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neola Medical stock

Gross Margin of Neola Medical is -1,176.96 % in 2021.

Gross Margin of Neola Medical changed from -25,329.03 % to -1,176.96 %, representing a -95.35% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Neola Medical since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Neola Medical with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Neola Medical

All Key Metrics — Neola Medical